Introduction
Tirzepatide is a synthetic 39-amino-acid peptide that is frequently referenced in receptor-pharmacology and in vitro metabolic research because of its dual binding affinity at two incretin receptors. This article describes how the peer-reviewed literature characterizes the molecule. It is a laboratory reference only and makes no statement regarding use in humans or animals.
Structural Overview
Tirzepatide is a single-chain peptide engineered with a fatty-acid moiety that the literature associates with extended stability in laboratory assay conditions. Its reported molecular weight is approximately 4813 g/mol. The molecule is most commonly classified in research as a dual GIP / GLP-1 receptor binding peptide.
The Two Receptors Studied
Research on tirzepatide centers on its interaction with two G-protein-coupled receptors that are well established targets in metabolic-signaling research:
- The GIP receptor (glucose-dependent insulinotropic polypeptide receptor), studied extensively in cell-based signaling assays.
- The GLP-1 receptor (glucagon-like peptide-1 receptor), a long-standing focus of in vitro endocrine research.
The literature describes tirzepatide as notable for engaging both receptors, which is why it is often used as a reference compound in comparative receptor-binding studies.
Role in Metabolic Research Models
In laboratory research, tirzepatide appears in receptor-binding assays, cyclic-AMP accumulation studies in transfected cell lines, and other bench experiments designed to characterize incretin-receptor signaling. These studies are conducted on cells or isolated systems and do not involve any claim about living subjects.
Analytical Characterization
Research-grade tirzepatide is supplied lyophilized and characterized by reversed-phase HPLC for purity, with identity confirmed by mass spectrometry. FYH Peptides documents batch-specific HPLC purity on each Certificate of Analysis. Standard handling for the lyophilized peptide follows ordinary laboratory practice: storage at −20 °C, protected from light and moisture.
Summary
Tirzepatide is a synthetic dual-incretin-receptor peptide studied widely in in vitro metabolic research. The receptor pharmacology above reflects published research focus and is provided purely as a laboratory reference, with no implication of use in humans or animals.
Published Research
Selected peer-reviewed literature indexed on NCBI PubMed. Listed for laboratory reference only — FYH Peptides makes no claim regarding the conclusions of any cited author.
- 1. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Aronne LJ, Sattar N, Horn DB, et al. · JAMA · 2024 PubMed · DOI
- 2. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Frías JP, Davies MJ, Rosenstock J, et al. · The New England journal of medicine · 2021 PubMed · DOI
- 3. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Nicholls SJ, Bhatt DL, Buse JB, et al. · American heart journal · 2024 PubMed · DOI
- 4. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. · JAMA internal medicine · 2024 PubMed · DOI
- 5. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. Loomba R, Hartman ML, Lawitz EJ, et al. · The New England journal of medicine · 2024 PubMed · DOI